Antonio Troia

Learn More
BACKGROUND AND OBJECTIVE Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's(More)
Hydroxycarbamide (HC) is a pharmacological agent capable of stimulating fetal haemoglobin (HbF) production during adult life. High levels of HbF may ameliorate the clinical course of β-thalassaemia and sickle cell disease. The efficacy of HC for the treatment of thalassaemia major and thalassaemia intermedia is variable. Although an increase of HbF has been(More)
Increased expression of fetal haemoglobin (HbF) may ameliorate the clinical course of beta-thalassemia and sickle cell disease. Some pharmacological agents, such as hydroxycarbamide (HC), can increase fetal haemoglobin synthesis during adult life. Cellular selection and/or molecular mechanisms have been proposed to account for this increase. To explore the(More)
Laparoscopic ventral hernia repair (LVHR) is a well-established approach for the repair of abdominal wall hernias in selected patients due to reductions in postoperative morbidity, length of stay, cost, and infection. Less well established is the choice of barrier mesh necessary in completing LVHR which has been primarily based upon knitted mesh(More)
A case of diabetic foot in a patient with advanced diabetes is presented. The correct diagnostic approach was analyzed based on the reasoned combination of available diagnostic imaging procedures (color-Doppler US, CT-angiography, MR-angiography and digital subtraction angiography) and on the clinician's instances. Angiographic findings contraindicated(More)
Phenotypic improvement of hemoglobinopathies such as sickle cell disease and β-thalassemia (β-thal) has been shown in patients with high levels of Hb F. Among the drugs proposed to increase Hb F production, hydroxyurea (HU) is currently the only one proven to improve the clinical course of these diseases. However, Hb F increase and patient's response are(More)
Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies. Hydroxyurea (HU) is the only inducer approved for the treatment of these diseases able to stimulate HbF production but patients' response is highly variable indicating the utility of the identification of pharmacogenomic biomarkers in order to predict(More)
  • 1